Allos Therapeutics, Inc. Release: Data Suggests Treatment with FOLOTYN(R) Reverses Trend of Progressive Resistance Observed in Patients with Drug-Resistant Relapsed or Refractory Peripheral T-Cell Lymphoma

LUGANO, Switzerland--(BUSINESS WIRE)--Allos Therapeutics, Inc. (NASDAQ: ALTH) today reported results from a retrospective analysis of data from the Company’s pivotal PROPEL trial which suggested that treatment with single-agent FOLOTYN® (pralatrexate injection) may result in increased response rates and progression-free survival relative to the immediate prior line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The analysis assessed those patients enrolled in the PROPEL trial who had received two or more lines of therapy prior to enrolling in the study and receiving FOLOTYN. Data were presented at the 11th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland (June 15-18).